with Braak stage for neurofibrillary tangles (NFTs) and senile plaques (SPs), and BBAR stage for Lewy body (LB) pathology (Saito Y et al 2004). Di- agnosis of AD is based on NFT stage equal to or more than 4 and SP stage C (Murayama et al 2004). Diagnosis of DLB is based on the involvement of spinal cord, peripheral autonomic nervous system and CA2-3 of hippo- campus with LB pathology, in addition to limbic and/ or neocortical in- volvement defined by the third DLB Consensus Guideline. Results: Significant correlation was present between the NFT or SP Stage and CSF tau, ptau, tau/Aß ratio or ptau/Aß ratio (p < 0.05). Significant inverse cor- relation was present between the LB Stage and 5-HIAA, and the NFT or SP Stage and Aß 1-42 (p < 0.05). Among the 73 cases examined, seven cases of AD, five cases of DLB and four cases of DLB+AD were included. HVA and tau in CSF was significantly higher in AD than in DLB as ex- pected. In addition, 5-HIAA and tau/Aß ratio in AD was higher than that in DLB or DLB+AD (p < 0.05). Conclusions: This is the first report to show correlation with CSF tau, ptau and Aß, as well as 5-HIAA and HVA for Alzheimer and Lewy body pathology. This study highlighted usefulness of combined evaluation of AD and PD biomarkers for differential diagnosis of AD, DLB and their combination. P2-052 SAPP-a AND SAPP-b LEVELS IN ALZHEIMER’S DISEASE, LEWY BODY AND PARKINSON’S DISEASE DEMENTIA PATIENTS AND THEIR CORRELATION WITH CLINICAL DIAGNOSIS Ezra Mulugeta 1 , Ragnhild Skogseth 1 , Henrik Zetterberg 2 , Kaj Blennow 3 , Elisabet Londos 4 , Dag Aarsland 1 , 1 Stavanger University Hospital, Stavanger, Norway; 2 University of Gothenburg, Gothenburg, Sweden; 3 University of Gothenburg, Molndal, Sweden, M€ olndal, Sweden; 4 Research Unit, Department of Clinical Sciences, Malm€ o, University of Lund, Sweden, Malmø, Sweden. Background: Cleavage of amyloid precursor protein (APP) by a-and ß-sec- retases generates soluble proteins known as sAPPa and sAPPß, while Aß42 is a product of the sequential cleavage of APP by ß-, and g-secretase. Utility of sAPPa and sAPPß as potential predictive and diagnostic markers for neu- rodegenerative diseases remains ambiguous, as only few and inconsistent results are available. Especially, there are no studies reported on the levels of sAPPa and sAPPß in patients with dementia with Lewy-bodies (DLB) and dementia associated with Parkinson’s disease (PDD). Objective: To ex- amine the CSF level of sAPPa and sAPPß in patients with AD, DLB, PDD and normal controls (NC), and to explore their clinical and neurochemical correlates. Methods: After standardized diagnostic procedures, 107 sub- jects were included: 50 AD, 23 DLB, 22 PDD and 12 NC. CSF levels of sAPPa and sAPPß and other proteins were determined using commercial multiplex assay kit. Cognition was assessed using MMSE. Non-parametric statistical analyses were used. Results: No significant differences were ob- served in the levels of sAPPa and sAPPß between the different disease groups. A significant correlation between sAPPß and MMSE score was ob- served both in the total group (rho 0.38, p < .01), in the AD (rho 0.43, p < .05) and DLB/PDD (rho ¼ 0.37, p < .05) groups, whereas sAPPa correlated with MMSE in the total group only (rho ¼ 0.2, p < .05). Finally, sAPPa and sAPPß levels correlated significantly with Aß38, Aß40, Aß42 Tau and P- Tau 281 in the DLB/PDD group, but not in the AD group. Conclusions: CSF sAPPa and sAPPß did not differ between AD, DLB, PDD and NC, but the observed correlation between MMSE score and sAPPß suggests an association with the disease process. The differential association between sAPPa / sAPPß and Aß and tau species in DLB/PDD compared to AD suggests a possible relationship with alpha-synuclein neurodegen- eration. P2-053 FACTORS ASSOCIATED WITH COGNITIVE AND FUNCTIONAL RESILIENCE DESPITE MOLECULAR EVIDENCE OF ALZHEIMER’S DISEASE PATHOLOGY Selamawit Negash 1 , Sharon Xiangwen Xie 1 , Christos Davatzikos 1 , David Wolk 1 , Steven Arnold 1 , 1 University of Pennsylvania, Philadelphia, Pennsylvania, United States. Background: The correlation between neuropathological lesions and cog- nition is modest. Some individuals remain cognitively intact amidst signif- icant accumulations of Alzheimer’s disease (AD) pathology, while many others manifest cognitive symptoms and dementia. The aim of the present study was to examine cognitive and cerebral reserve factors associated with resilient functioning in the setting of AD pathology. Methods: Univer- sity of Pennsylvania Alzheimer’s Disease Center research participants with biochemical biomarker evidence of AD pathology (cerebrospinal fluid Aß 1-42 & < 192 pg/ml) and comparable medial temporal lobe atrophy were categorized by Clinical Dementia Rating (CDR) scale score as AD De- mentia (CDR > 1) or AD Resilient (CDR < 0.5). Groups were compared for a variety of demographic, clinical, and neuroimaging variables to identify factors that are associated with resilience to AD pathology. Results: A uni- variate model identified education and intracranial volume (ICV) as signif- icant covariates. In a multivariate model with backward selection procedure, ICV was retained as a factor most significantly associated with resilience. The interaction term between ICV and education was not significant, sug- gesting that larger cranial vault size is associated with resilience even in the absence of more education. Conclusions: Premorbid brain volume, as measured through ICV, provided protection against clinical manifestations of dementia despite evidence of significant accumulations of AD pathology. This finding provides support for the brain reserve hypothesis of resilience to AD. Acknowledgment: Marian S. Ware Alzheimer’s Program. P2-054 ALOIS - THE NEXT PHASE: A COMPREHENSIVE STUDY-BASED REGISTER OF DIAGNOSTIC STUDIES (WWW.MEDICINE.OX.AC.UK/ALOIS) Anna Noel-Storr 1 , Rupert McShane 2 , 1 Cochrane Dementia Group, Oxford, United Kingdom; 2 Cochrane Dementia Group, Oxford University, Oxford, United Kingdom. Background: ALOIS is a freely available, comprehensive register of de- mentia studies which was launched at ICAD in 2009 by the Cochrane De- mentia and Cognitive Improvement Group (CDCIG). The register is ‘study-based’ which means that references about the same trial have been grouped under one parent record. ALOIS now holds details of over 4200 treatment trials. The site receives on average around 3500 page views per month. Users can view key details about a study such as number of partic- ipants, intervention duration, outcomes, dates of study, any study IDs, all re- lated references. ALOIS is maintained by a group of graduate level volunteers, many of whom are, or were, caregivers of patients with demen- tia. They are supported by the Cochrane editorial unit. ALOIS is a valuable resource for the teaching of evidence-based dementia. The Cochrane De- mentia Group CDCIG is now undertaking a programme of reviews of stud- ies of diagnostic tests. This complements the existing portfolio of reviews about treatments. ALOIS is now being developed to support these reviews of diagnostic tests. Methods: There are two key strands to creating a com- prehensive register of studies of diagnostic test accuracy (DTA): 1. System- atic identification of studies for inclusion:  A sensitive search strategy was designed and was run in MEDLINE to re- trieve articles published between 2000 and 2010 in which cross-sectional di- agnosis of dementia or prediction of progression to dementia were outcomes.  A team of paid assessors then screened the results. They identified any po- tential reference to studies of cross-sectional or longitudinal design in which diagnosis of dementia or cognition was an outcome/significant aspect.  The resulting references were then examined and divided according to di- agnostic method/test and study design.  Studies of biomarkers as predictors of progression from MCI to dementia were then examined in more detail. Full papers were obtained and the fol- lowing information extracted:  Participants and their health condition at baseline, and  Conversion figures and accuracy data if given Poster Presentations P2 S324